Differential Effect of the Metabolic Syndrome on the Incidence of Retinal Vein Occlusion in the Korean Population: A Nationwide Cohort Study

Dong Hui Lim¹,²,*, Kyoung Yoon Shin³,*, Kyungdo Han⁴, Se Woong Kang¹, Don-Il Ham¹, Sang Jin Kim¹, Yong Gyu Park⁵, and Tae-Young Chung¹

¹ Department of Ophthalmology, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea
² Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea
³ Department of Ophthalmology, Seongnam Citizens Medical Center, Seongnam, Republic of Korea
⁴ Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea
⁵ Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Correspondence: Tae-Young Chung, Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, #81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea. e-mail: tychung@skku.edu

Received: May 12, 2020
Accepted: August 10, 2020
Published: December 8, 2020

Keywords: retinal vein occlusion; metabolic syndrome; blood pressure; epidemiology

Citation: Lim DH, Shin KY, Han K, Kang SW, Ham D-I, Kim SJ, Park YG, Chung T-Y. Differential effect of the metabolic syndrome on the incidence of retinal vein occlusion in the Korean population: A nationwide cohort study. Trans Vis Sci Tech. 2020;9(13):15, https://doi.org/10.1167/tvst.9.13.15

Purpose: To investigate the impact of the metabolic syndrome (METS) on the incidence of retinal vein occlusion (RVO).

Methods: This is a retrospective cohort study using Korean National Health Insurance System data. 23,153,600 subjects without previous history of RVO underwent a National Health Screening Program examination between 2009 and 2012. They were monitored for RVO development (registration of diagnostic code for RVO) until 2015. Presence of METS was defined using the data from the National Health Screening Program examination according to the revised criteria of the National Cholesterol Education Program Adult Treatment Panel III. A multivariate adjusted Cox regression analysis was used to reveal hazard ratios and 95% confidence interval for RVO development in the presence of METS.

Results: The age of the subjects was 47.64 ± 13.51 years. In this cohort, 11,747,439 (50.7%) were male, 11,406,161 (49.3%) were female, and 6,398,071 subjects (27.6%) were diagnosed with METS. The overall incidence of RVO was 0.947 per 1000 person-years. The adjusted hazard ratio of RVO in the presence of METS was 1.458 (95% confidence interval, 1.440–1.475; P < 0.001) after adjusting for age, sex, smoking status, alcohol consumption, physical activity, and income. Among all of the criteria for METS diagnosis, elevated blood pressure was the greatest risk for RVO development (adjusted hazard ratio, 1.610; 95% confidence interval, 1.589–1.631; P < 0.001).

Conclusions: METS and each of diagnostic criteria was associated with an increased risk of RVO development. Elevated blood pressure seems to be especially important factors for RVO development.

Translational Relevance: Our results provide information about the link between METS and RVO.

Introduction

Retinal vein occlusion (RVO) is one of the most prevalent retinal vascular disease worldwide.¹–⁴ RVO is regarded to be an arterial disease; retinal arterial stiffening causes compression of the retinal vein, provides hemodynamic changes, and leads to obstruction of venous return of the retinal circulation.²–⁵ Systemic vascular diseases including arterial hypertension,⁶–⁸ diabetes mellitus,⁷–⁹ atherosclerosis, cardiovascular disease,¹⁰,¹¹ and thrombophilia¹² are considered to be major risk factors for RVO occurrence.

The metabolic syndrome (METS) is a set of diseases including high blood pressure (BP), hyperglycemia, dyslipidemia, and central obesity. These metabolic
abnormalities frequently coexist, and the prevalence of METS has been continuously increasing in recent decades. METS is thought to be a distinct entity that affects a large proportion of the adult population\textsuperscript{13,14} and is well-known to be strongly related to the development of cerebrocardiovascular diseases\textsuperscript{15,16}. Although the vascular compromises complicating METS are well-established in the literature, there are only limited reports regarding the link between METS and RVO, the main vision threatening vascular diseases in the ophthalmology\textsuperscript{17}. Furthermore, there has not been any longitudinal study of the association between METS and the development of RVO yet. Given the high prevalence of METS in developed countries, elucidating the association of METS and the risk of RVO would promote the understanding of the burden of METS on the ophthalmic field.

Therefore, we investigated the association between METS and the risk of RVO development through a nationwide, large-scale retrospective cohort study based on the Korean National Health Insurance Database from 2002 to 2015.

**Methods**

**Study Setting**

The data analyzed in this study were derived from the database of the Korean National Health Insurance Service (NHIS). The Korean NHIS is an obligatory public health insurance system that provides universal health coverage to all Koreans except for Medicaid beneficiaries in the lowest income bracket (approximately 3% of the population). Hence, the NHIS comprises a complete set of health information that covers about 51 million people in the Korean population.

The Korean NHIS offers a biennial National Health Screening Program (NHSP) to all members older than 30 years of age. The Korean NHIS collects all necessary information for the reimbursement of each medical service provided, including basic patient information, identifier for the clinic or hospital, disease code, and costs incurred\textsuperscript{18}. Patient information includes age, sex, average monthly insurance premium, and residential area (categorized as city area, metropolitan area, and rural area), as well as a completed questionnaire (past medical history, health behavior), anthropometric exam (body mass index [BMI], BP), and laboratory tests (blood sugar, cholesterol, and others)\textsuperscript{19}. The Korean NHIS database has, therefore, been widely used in various epidemiological studies\textsuperscript{20}. Moreover, diagnostic codes based on the Korean Standard Classification of Diseases have been used in South Korea, and these are comparable to the International Classification of Diseases. The details of the Korean NHIS are described in previous reports\textsuperscript{21,22}.

**Study Population**

A total of 23,503,802 subjects who participated in the NHSP at least once between 2009 and 2012 were initially enrolled. Among these, 50,940 subjects who were less than 20 years old, 196,231 subjects with a diagnostic code of RVO (Korean Standard Classification of Diseases code: H34.8) during the washout period (2002–2008) and 103,031 subjects with incomplete sets of data for the assessment of METS were excluded. Hence, this study included 23,153,600 subjects who were more than 20 years old without previous history of RVO who underwent a health examination at least once between January 1, 2009, and December 31, 2012. All subjects were monitored for development of RVO until December 31, 2015. If patients were diagnosed with RVO more than once during the monitoring period, the first visit was considered to be the RVO incident date. This date was used for statistical analyses. Eligibility criteria are summarized in Figure 1.

The study adhered to the Declaration of Helsinki, and the study protocol was reviewed and approved by...
the Institutional Review Board of Samsung Medical Center (SMC 2018-05-190). The board waived the requirement for informed consent as the NHIS anonymized all participants according to strict confidentiality guidelines.

Measurements and Definition of the METS and Other Risk Factors

For those who underwent health screening more than once between 2009 and 2012, the first health screening measures were used for the analysis.

BP was measured while the subject was in a seated position after 5 minutes of rest during the daytime using automated sphygmomanometer. Blood samples were collected after overnight fasting. The serum levels of glucose, total cholesterol, triglycerides (TG), high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein cholesterol were measured using the enzymatic method.23 METS was defined based on the revised criteria of the National Cholesterol Education Program Adult Treatment Panel III.24 According to the guideline, three or more of the following five components constitute a diagnosis of METS: (i) elevated waist circumference (WC) (≥90 cm for men and ≥85 cm for women, according to the Korean Society for the Study of Obesity’s cut-off points for central or abdominal obesity)25; (ii) elevated TG level (≥150 mg/dL) or taking medications for hypertriglyceridemia; (iii) reduced HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women); (iv) elevated BP (systolic BP of ≥130 mm Hg or diastolic BP of ≥85 mm Hg) or receiving antihypertensive treatment; and (v) elevated fasting glucose (≥100 mg/dL) or taking medications for increased glucose.26

If the systolic BP was 140 mm Hg or higher or the diastolic BP was 90 mm Hg or higher, the fasting blood glucose level was 126 mg/dL or higher, or total cholesterol was 240 mg/dL or higher, subjects were considered to have hypertension, diabetes mellitus, and dyslipidemia, respectively. Additionally, if subjects were prescribed with antihypertensive, glucose-lowering, or lipid-lowering medication (correspond with ATC code C02 [antihypertensive], A10 [glucose lowering], and C10 [lipid lowering], respectively) in the year of NHSP with corresponding a diagnostic code (hypertension, I15; diabetes, E11–E14; dyslipidemia, E78), they were considered to have hypertension, diabetes mellitus, and dyslipidemia, respectively. Stroke was defined according to diagnostic codes (I63 and I64) for diagnoses made during hospitalization together with brain computed tomography or magnetic resonance imaging. Heart disease included myocardial infarction (diagnostic codes I21 and I22) and heart failure (diagnostic code I50) diagnosed during hospitalization.27 The presence of chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m² from serum creatinine measured by kinetic Jaffé method or end point Jaffé method.

Lifestyle variables were recorded using the NHSP questionnaire. The definition of lifestyle variables was as follows.28 Smoking status was categorized into three groups: nonsmokers, current smokers who had smoked 100 cigarettes or more in their lifetime, and former smokers, who had smoked in the past but had since quit at least 1 month prior. Alcohol consumption status was categorized into three groups: nondrinker, those who drank less than 30 g/d on average and those who drank more than 30 g/d. Regular exercise was defined as strenuous physical activity that was performed for at least 30 minutes at least five times in a week. This factor was ascertained through subject questionnaires.23 BMI was defined as the weight in kilograms divided by the square of height in meters. Subjects with income of less than the lower 20 percentile were defined to have a low income. Hospitals wherein these health examinations were performed were certified by the NHIS and subjected to regular quality control.

Statistical Analysis

Data are summarized as numbers with percentages for categorical variables, and mean values with standard deviations are used for continuous variables. Multivariate adjusted Cox regression analysis was conducted to examine RVO development hazard ratios (HR) and associated 95% confidence intervals (CIs) for risk factors of interest after adjusting for age, sex, smoking, alcohol consumption, and income level. These risk factors included the presence of METS, hypertension, diabetes, dyslipidemia, and each of the five components constituting a diagnosis of METS. Further, the HR for the number of METS components was also evaluated. A P value of less than 0.05 was considered statistically significant. Statistical Analysis System software version 9.4 (SAS Inc, Cary, NC) was used for all analyses.

Results

Baseline characteristics of the study population are presented in Table 1. The average age of the study subjects was 47.64 ± 13.51 years; 11,747,439 (50.7%) were male and 11,406,161 (49.3%) were female.
The total number of subjects without METS was 16,755,529 and with METS was 6,398,071. Among subjects without METS, 59,515 subjects (0.36%) were diagnosed with RVO within the study period, and 58,177 subjects (0.91%) with METS developed RVO. Compared with participants without METS, those with METS were more likely to be male; over 65 years old; and have higher systolic BP and diastolic BP, blood glucose, total cholesterol, low-density lipoprotein cholesterol, and TG, and lower HDL cholesterol. Diabetes mellitus, hypertension, dyslipidemia, stroke, heart disease, and CKD were all more prevalent in participants with METS ($P < 0.001$).

Table 2 shows the independent associations between specific components of METS and RVO. Each model includes the five syndrome components as independent variables. Multivariable Cox regression analyses adjusted for confounders were performed, and HR on RVO development and its 95% CI by METS and five syndrome components were obtained. The confounders adjusted for in each model are as follows: model 1, age and sex; model 2, age, sex, smoking...
Table 2. Cox Regression Analysis on RVO Development by METS and Its Components

| METS          | Model 1a | Model 2b | Model 3c |
|---------------|----------|----------|----------|
| No            | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes           | 1.455* (1.438–1.473) | 1.458* (1.440–1.475) | 1.363* (1.345–1.381) |

Components of METS

| WC1          | Model 1a | Model 2b | Model 3c |
|--------------|----------|----------|----------|
| No           | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes          | 1.214* (1.199–1.230) | 1.212* (1.197–1.227) | 1.011† (0.995–1.027) |

| BP2          | Model 1a | Model 2b | Model 3c |
|--------------|----------|----------|----------|
| No           | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes          | 1.612* (1.591–1.634) | 1.610* (1.589–1.631) | 1.532* (1.511–1.553) |

| Glucose3     | Model 1a | Model 2b | Model 3c |
|--------------|----------|----------|----------|
| No           | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes          | 1.289* (1.274–1.304) | 1.288* (1.273–1.303) | 1.239* (1.224–1.254) |

| TGs4         | Model 1a | Model 2b | Model 3c |
|--------------|----------|----------|----------|
| No           | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes          | 1.245* (1.230–1.259) | 1.253* (1.238–1.267) | 1.182* (1.168–1.197) |

| High-density lipoprotein5 | Model 1a | Model 2b | Model 3c |
|---------------------------|----------|----------|----------|
| No                        | 1 (Ref.) | 1 (Ref.) | 1 (Ref.) |
| Yes                       | 1.267* (1.252–1.282) | 1.270* (1.255–1.286) | 1.214* (1.199–1.229) |

HRs (95% CI) were calculated using a Cox proportional hazards model.

aAdjusted for age and sex.
bAdjusted for age, sex, smoking status, alcohol consumption, physical activity, and income level.
cAdjusted for age, sex, smoking status, alcohol consumption, physical activity, income level, and BMI.

1Elevated WC (≥90 cm for men and ≥85 cm for women, according to the Korean Society for the Study of Obesity’s cut-off points for central or abdominal obesity).
2Elevated BP (systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or receiving antihypertensive treatment).
3Elevated fasting glucose (≥100 mg/dL) or taking medications for increased glucose.
4Elevated TGs level (≥150 mg/dL) or taking medications for hypertriglyceridemia.
5Reduced high-density lipoprotein (<40 mg/dL in men and <50 mg/dL in women).

* P < 0.001.
† P = 0.177.

status, alcohol consumption, physical activity, and income; and model 3, age, sex, smoking status, alcohol consumption, physical activity, income, and BMI. HRs and 95% CIs for RVO according to the presence of METS and each of the five METS criteria were calculated. All of the METS criteria were associated with a significantly increased risk of RVO. The adjusted HRs of RVO according to the presence of METS were 1.455 (95% CI, 1.438–1.473; P < 0.001) in model 1, 1.458 (95% CI, 1.440–1.475; P < 0.001) in model 2, and 1.363 (95% CI, 1.345–1.381; P < 0.001) in model 3. For those with the WC criterion of METS fulfilled, the adjusted RVO HRs were 1.214 (95% CI, 1.199–1.230; P < 0.001) in model 1, 1.212 (95% CI, 1.197–1.227; P < 0.001) in model 2, and 1.011 (95% CI, 0.995–1.027; P = 0.177) in model 3. For those satisfying the BP criterion of METS, the adjusted RVO HRs were 1.612 (95% CI, 1.591–1.634; P < 0.001) in model 1, 1.610 (95% CI, 1.589–1.631; P < 0.001) in model 2, and 1.532 (95% CI, 1.511–1.553; P < 0.001) in model 3. For the elevated glucose component of METS diagnosis, the adjusted RVO HRs were 1.289 (95% CI, 1.274–1.304; P < 0.001) in model 1, 1.288 (95% CI, 1.273–1.303; P < 0.001) in model 2, and 1.239 (95% CI, 1.224–1.254; P < 0.001) in model 3. The TG and HDL cholesterol components of METS showed similar HR increases, and these results are listed in Table 2.

The RVO incidence rate showed a dose-dependent pattern as the number of METS components satisfied increased (Table 3). The overall incidence of RVO was 0.947 per 1000 person-years. Those with no METS criteria satisfied showed an RVO incidence of
**Table 3.** Incidence Rate and HR of RVO According to the Number of METS Components Individuals Have

| No. of METS Components | Event | Person-Years | Incidence Rate<sup>a</sup> | HR (95% CI)            | Model 1<sup>b</sup> | Model 2<sup>c</sup> | Model 3<sup>d</sup> |
|------------------------|-------|--------------|-----------------------------|-----------------------|---------------------|---------------------|---------------------|
| 0                      | 10,802 | 32,466,658.41| 0.33                        | 1 (Ref.)              | 1 (Ref.)            | 1 (Ref.)            |
| 1                      | 21,852 | 31,927,227.21| 0.68                        | 1.450<sup>e</sup> (1.417–1.485) | 1.454<sup>e</sup> (1.42–1.488) | 1.429<sup>e</sup> (1.396–1.463) |
| 2                      | 26,861 | 25,530,204.28| 1.05                        | 1.755<sup>e</sup> (1.715–1.795) | 1.761<sup>e</sup> (1.721–1.802) | 1.704<sup>e</sup> (1.664–1.744) |
| 3                      | 25,850 | 18,153,925.23| 1.42                        | 2.001<sup>e</sup> (1.955–2.048) | 2.010<sup>e</sup> (1.964–2.058) | 1.922<sup>e</sup> (1.875–1.969) |
| 4                      | 21,350 | 11,324,723.38| 1.89                        | 2.248<sup>e</sup> (2.194–2.303) | 2.257<sup>e</sup> (2.203–2.312) | 2.136<sup>e</sup> (2.082–2.192) |
| 5                      | 10,977 | 4,751,745.48 | 2.31                        | 2.375<sup>e</sup> (2.31–2.441) | 2.385<sup>e</sup> (2.32–2.452) | 2.221<sup>e</sup> (2.156–2.289) |

<sup>a</sup>RVO incidence per 1000 person-years.
<sup>b</sup>HRs (95% CI) with a Cox proportional hazards model adjusted for age and sex.
<sup>c</sup>Adjusted for age, sex, smoking status, alcohol consumption, physical activity, and income level.
<sup>d</sup>Adjusted for age, sex, smoking status, alcohol consumption, physical activity, income level, and BMI.
<sup>*</sup><em>P</em> < 0.001.

0.33 per 1000 person-years, whereas those who met all five criteria showed a RVO incidence rate of 2.31 per 1000 person-years. Figure 2 demonstrates the HRs of RVO occurrence by every combination of METS diagnostic criteria after adjusting confounders using model 3. The combination of BP and WC criteria fulfillment increased the risk of RVO; the HR was 2.005 (95% CI, 1.933–2.080; <em>P</em> < 0.001). BP and HDL cholesterol criteria fulfillment also increased the risk of RVO; the HR was 2.015 (95% CI, 1.938–2.094; <em>P</em> < 0.001). Other details are presented in Figure 2.

Additional subgroup HR analyses for RVO development and METS were performed and are presented in Figure 3 (model 3). Subjects were grouped by age, sex, smoking, alcohol consumption, amount of physical activity, income level, and history of CKD, stroke, and heart diseases. For subjects below the age of 65, the presence of METS increased the risk of RVO occurrence significantly compared with those over the age of 65 (HR, 1.443 for age <65 years, 1.161 for age ≥65 years; <em>P</em> for interaction < 0.0001). METS increased the risk of RVO development greater in the smoking subgroup than in the nonsmoking subgroup (HR, 1.500 for current smoker, 1.344 for nonsmoker and past smoker, <em>P</em> for interaction < 0.0001) and in the CKD subgroup than the non-CKD subgroup (HR, 1.468 for CKD patients, 1.344 for non-CKD patients, <em>P</em> for interaction < 0.0001). Other variables did not show significant differences.

To evaluate the effect of METS itself, excluding hypertension and diabetes, the associations between METS components and RVO were analyzed after excluding those who have hypertension or diabetes at the baseline (Table 4). Even after excluding subjects with hypertension or diabetes, METS did increase the risk of RVO occurrence.

**Discussion**

This nationwide population-based study demonstrates that METS and each of its diagnostic criteria increase the risk of RVO occurrence. Our team previously reported that lower HDL cholesterol level is associated with a greater risk of RVO using the claims data from NHIS. The previous study focused only on HDL cholesterol and measured RVO risk adjusting all other variables including HTN, DM, and dyslipidemia. In addition to the previous findings, the present study further focused on METS and each five components and revealed the association with RVO development. Previous reports in the literature regarding the association of METS and RVO defined METS as a combination of hypertension, diabetes, and dyslipidemia, which is a lot different from the widely accepted METS definition. In this point, our study is the first report to show an association between METS and RVO with a proper METS definition. We also analyzed the risk of RVO development associated with the number of METS diagnostic components satisfied and found that the BP criterion was the most important for RVO development. In addition, we investigated the impact of METS on various subgroups and compared the outcomes. Therefore, the current study may provide information in establishing effective and tailored treatment strategies.

The National Cholesterol Education Program’s Adult Treatment Panel III report defined METS as a specific entity that requires more clinical attention. Previous clinical studies showed that microvascular diseases, including RVO, may be an integral component of METS. These studies said the change of the microcirculation in the aspect of structure and function...
Figure 2. HR for RVO occurrence by combinations of METS diagnostic criteria. HRs with 95% CI were calculated using a Cox proportional hazards model adjusting age, sex, smoking status, alcohol consumption, physical activity, income, and BMI. * P < 0.0001. W, elevated WC (≥90 cm for men and ≥85 cm for women, according to the Korean Society for the Study of Obesity’s cut-off points for central or abdominal obesity); B, elevated BP (systolic BP of ≥130 mm Hg, diastolic BP of ≥85 mm Hg, or receiving antihypertensive treatment); G, Elevated fasting glucose (≥100 mg/dL) or taking medications for increased glucose; T, elevated TG level (≥150 mg/dL) or taking medications for hypertriglyceridemia; H, reduced high-density lipoprotein (<40 mg/dL in men and <50 mg/dL in women).

| Number of components | Combination | Hazard ratio (95% CI) | Forest plot |
|----------------------|------------|-----------------------|-------------|
| 0                    | None       | 1                     |             |
| 1                    | W          | 1.395 (1.324,1.469)   |             |
|                      | B          | 1.787 (1.742,1.833)   |             |
|                      | G          | 1.360 (1.314,1.407)   |             |
|                      | T          | 1.120 (1.070,1.173)   |             |
|                      | H          | 1.137 (1.091,1.186)   |             |
| 2                    | WB         | 2.005 (1.933,2.080)   |             |
|                      | WG         | 1.709 (1.604,1.821)   |             |
|                      | WT         | 1.357 (1.254,1.468)   |             |
|                      | WH         | 1.443 (1.326,1.571)   |             |
|                      | BG         | 1.990 (1.934,2.048)   |             |
|                      | BT         | 1.728 (1.664,1.794)   |             |
|                      | BH         | 2.015 (1.938,2.094)   |             |
|                      | GT         | 1.449 (1.371,1.530)   |             |
|                      | GH         | 1.508 (1.416,1.607)   |             |
|                      | TH         | 1.424 (1.369,1.482)   |             |
| 3                    | WBG        | 2.176 (2.097,2.257)   |             |
|                      | WBT        | 1.924 (1.834,2.019)   |             |
|                      | WBH        | 2.158 (2.043,2.278)   |             |
|                      | WGT        | 1.722 (1.590,1.866)   |             |
|                      | WGH        | 1.870 (1.688,2.072)   |             |
|                      | WTH        | 1.580 (1.482,1.684)   |             |
|                      | BGT        | 2.020 (1.947,2.095)   |             |
|                      | BGH        | 2.154 (2.057,2.256)   |             |
|                      | BTH        | 2.106 (2.045,2.169)   |             |
|                      | GTH        | 2.001 (1.919,2.086)   |             |
| 4                    | WBGT       | 2.188 (2.099,2.280)   |             |
|                      | WBGH       | 2.139 (2.023,2.261)   |             |
|                      | WBTH       | 2.144 (2.071,2.220)   |             |
|                      | WGTH       | 2.010 (1.895,2.133)   |             |
|                      | BGTH       | 2.514 (2.446,2.584)   |             |
| 5                    | WBGTH      | 2.378 (2.310,2.448)   |             |

in the skin and skeletal muscles in METS patients or with specific components of METS, such as abdominal obesity, diabetes mellitus, dyslipidemia, and hypertension. These findings support our results that the presence of METS increases the risk of RVO and that the presence of each of the five METS diagnostic components is independently associated with an increased risk of RVO. This finding suggests the importance of the impact of each component on microvascular diseases, including RVO.

Interestingly, among the five diagnostic components, the impact of the BP criterion on RVO occurrence was particularly significant. A possible explanation for the greater impact of high BP on RVO occurrence in our study is that high BP directly induces shear-related injury to the vasculature and promotes...
vascular cell proliferation, whereas the other factors only indirectly damage arteries by modifying insulin sensitivity, lipid metabolism, and molecular susceptibility to lipid accumulation. Controlling BP is particularly important for prevention of RVO. Moreover, as shown in Figure 2, the HRs for the combination of BP and WC criteria and the combination of BP and HDL cholesterol criteria were more than 2.000. Because three criteria need to be fulfilled, these combinations are not sufficient for a METS diagnosis. However, the impact of these combinations on RVO development is comparable with that of METS. Hence, controlling those combinations of factors is of clinical importance.

The subgroup analysis for the impact of METS on RVO occurrence (Fig. 3) has revealed that METS has greater impact on younger subjects (age <65 years) and on subjects who smoke. Similar to the results of our study, there are many studies that demonstrate the lesser impact of METS on older patients. They reported that a lesser degree of risk of cardiovascular diseases in older participants with METS and suggested that METS in young participants may be different from that in older participants with different prognostic and treatment implications, although the exact mechanism is unclear and requires further investigation. Also, many studies reported that the combination of smoking and METS markedly increases risk of cardiovascular disease beyond that of either condition that concord with our study. Our results suggest that clinicians should pay extra attention to those who are young and smoking and thoroughly control METS components to decrease the risk of RVO.

A large proportion of the subjects with METS were diabetic and hypertensive in the current study. Because the risk of RVO occurrence should be high enough if the risk is defined by those who have diabetes or hypertension, the investigators wanted to evaluate the relationship between METS itself (which has not been advance to hypertension or diabetes yet) and RVO. Table 4 demonstrates that, even after excluding hypertension and diabetes, METS was associated with increased the risk of RVO occurrence. In addition, the increased BP and glucose level were associated with increased risk of RVO, meaning that the prehypertension and the impaired fasting glucose increases the risk of RVO.
Table 4. Cox Regression Analysis on RVO Development by METS and Its Components for Those Without Hypertension or Diabetes Mellitus

|                     | HR (95% CI)            |
|---------------------|------------------------|
|                     | Model 1a               | Model 2b               | Model 3c               |
| METS                |                        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.258* (1.231–1.285)   | 1.261* (1.234–1.289)   | 1.137* (1.111–1.163)   |
| Components of METS  |                        |                        |                        |
| WC†                 |                        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.210* (1.184–1.238)   | 1.209* (1.182–1.236)   | 0.984† (0.958–1.011)   |
| BP2                 |                        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.299* (1.274–1.325)   | 1.298* (1.273–1.323)   | 1.247* (1.223–1.272)   |
| Glucose3            |                        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.076* (1.054–1.098)   | 1.075* (1.053–1.097)   | 1.040* (1.019–1.062)   |
| TGs4                |                        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.135* (1.114–1.157)   | 1.144* (1.122–1.166)   | 1.074* (1.053–1.095)   |
| High-density lipoprotein5 |        |                        |                        |
| No                  | 1 (Ref.)               | 1 (Ref.)               | 1 (Ref.)               |
| Yes                 | 1.134* (1.112–1.157)   | 1.139* (1.117–1.162)   | 1.090* (1.068–1.112)   |

HRs (95% CI) were calculated using a Cox proportional hazards model.

*Adjusted for age and sex.
†Adjusted for age, sex, smoking status, alcohol consumption, physical activity, and income level.
‡Adjusted for age, sex, smoking status, alcohol consumption, physical activity, income level, and BMI.
1Elevated WC (≥90 cm for men and ≥85 cm for women, according to the Korean Society for the Study of Obesity’s cut-off points for central or abdominal obesity).
2Elevated BP (systolic BP ≥130 mm Hg, diastolic BP ≥85 mm Hg, or receiving antihypertensive treatment).
3Elevated fasting glucose (≥100 mg/dL) or taking medications for increased glucose.
4Elevated TGs level (≥150 mg/dL) or taking medications for hypertriglyceridemia.
5Reduced high-density lipoprotein (<40 mg/dL in men and <50 mg/dL in women).
*P < 0.001.
†P = 0.253.

The strengths of the present study include the long study period, large samples, and availability of sufficient clinical information to enable standardized identification of METS. The current study was representative of the entire Korean population; our data included 23,153,600 subjects, approximately one-half of that population. Also, the data included information between 2002 and 2015, and this scope enabled the current study to establish a washout period of 7 years to exclude patients who were previously diagnosed with RVO. The long washout period decreased the innate limitation of claims data-based epidemiologic studies by maximizing the identification of only true incident cases. In addition, our data included not only diagnostic codes, but also detailed clinical, information including income, health behavior, BP, WC, BMI, and laboratory tests that enabled reliable METS verification.

Our study had several limitations. First, RVO patients were identified by claims data from health care use, and this factor means we might have missed patients with asymptomatic RVO or those who were unable to access the health care system. Therefore, the RVO cases in our study should be regarded as clinically diagnosed RVO cases. Second, we were not able to confirm the RVO and METS diagnosis by reviewing the medical records. RVO diagnoses based on Korean Standard Classification of Diseases codes might be less accurate than the diagnoses confirmed from a medical record with fundus descriptions and images. Therefore, there is a chance that subjects without actual RVO
development are regarded as RVO cases in the present study. Nevertheless, registration of the diagnostic codes is made by expert ophthalmologists, and the ability to diagnose RVO has improved by technological advances in ocular imaging. In addition, in the cases of METS, the diagnosis was made accurately based on the examination data, and additionally medication code, thereby decreasing the concern about inaccuracy. Therefore, we believe that the current study provides a reliable diagnosis of RVO and METS. Third, we could not evaluate the type, severity, or extent of RVO. There is currently no specific code separating central RVO and branched RVO or representing the extent and severity of the disease. Further studies investigating these facets of RVO are required. Last, we were unable to address more detailed socioeconomic markers, such as residential area or inflammatory markers like C-reactive protein or white blood cell counts. Providing this information would have resulted in better study, and future research elucidating this point should be warranted.

In conclusion, we herein report a nationwide, population-based cohort study in South Korea highlighting the impact of METS on RVO development. We demonstrated that the components of METS contribute additively to the risk of RVO, and elevated BP significantly affects development of RVO. We also suggest that METS control should be more strongly emphasized for the younger population and for smokers to prevent RVO. This study would offer a better understanding on pathophysiology of RVO and offer insight into establishing effective clinical management of METS and RVO.

Acknowledgments

Supported by the National Research Foundation of Korea grant funded by the Korea government Ministry of Education (NRF-2018R1D1A1A02045884; Seoul, Korea), and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI19C0481, HC19C0142), which was received by Dong Hui Lim.

Tae-Young Chung designed the study. Dong Hui Lim, Kyoung Yoon Shin, and Kyungdo Han analyzed and interpreted the clinical data. Dong Hui Lim and Kyoung Yoon Shin wrote the final paper. Se Woong Kang, Don-Il Ham, Sang Jin Kim, Tae-Young Chung, and Yong Gyu Park reviewed the design, the results, and the final paper. Dong Hui Lim and Kyoung Yoon Shin equally contributed to the manuscript as the first authors. Tae-Young Chung contributed to the manuscript as the corresponding author. All authors read and approved the final manuscript.

Data Availability: The data used in the present study are prohibited from being shared. The raw data used in this study can be accessed at the request of qualified investigator through the Korea National Health Insurance system.

Disclosure: D. H. Lim, None; K. Y. Shin, None; K. Han, None; S. W. Kang, None; D.-I. Ham, None; S. J. Kim, None; Y. G. Park, None; T.-Y. Chung, None

* DHL and KYS contributed to this article equally as the first authors.

References

1. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56(4):281–299.
2. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res. 2005;24(4):493–519.
3. McIntosh RL, Rogers SL, Lim L, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1113–1123.e1115.
4. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094–1101.e1095.
5. Werther W, Chu L, Holekamp N, et al. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;129(3):326–331.
6. Johnston RL, Brucker AJ, Steinmann W, et al. Risk factors of branch retinal vein occlusion. Arch Ophthalmol. 1985;103(12):1831–1832.
7. Risk factors for branch retinal vein occlusion. The Eye Disease Case-control Study Group. Am J Ophthalmol. 1993;116(3):286–296.
8. Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol. 1996;114(5):545–554.
9. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141; discussion 141–133.
Cugati S, Wang JJ, Knudtson MD, et al. Retinal vein occlusion and vascular mortality: pooled data analysis of 2 population-based cohorts. *Ophthalmology*. 2007;114(3):520–524.

Bertelsen M, Linneberg A, Rosenberg T, et al. Comorbidity in patients with branch retinal vein occlusion: case-control study. *BMJ*. 2012;345:e7885.

Rehak M, Krcova V, Slavik L, et al. The role of thrombophilia in patients with retinal vein occlusion and no systemic risk factors. *Can J Ophthalmol*. 2010;45(2):171–175.

Schmidt MI, Duncan BB, Watson RL, et al. A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. *Diabetes Care*. 1996;19(5):414–418.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA*. 2002;287(3):356–359.

Moller DE, Flier JS. Insulin resistance—mechanisms, syndromes, and implications. *N Engl J Med*. 1991;325(13):938–948.

Golden SH, Folsom AR, Coresh J, et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. *Diabetes*. 2002;51(10):3069–3076.

Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. *J Ophthalmol*. 2014;2014:724780.

Shin DW, Cho J, Yang HK, et al. Impact of continuity of care on mortality and health care costs: a nationwide cohort study in Korea. *Ann Fam Med*. 2014;12(6):534–541.

Lee H, Cho J, Shin DW, et al. Association of cardiovascular health screening with mortality, clinical outcomes, and health care cost: a nationwide cohort study. *Prev Med*. 2015;70:19–25.

Chun SH, Cho B, Yang HK, et al. Performance on physical function tests and the risk of fractures and admissions: findings from a national health screening of 557,648 community-dwelling older adults. *Arch Gerontol Geriatr*. 2017;68:174–180.

Shin DW, Cho B, Guallar E. Korean National Health Insurance Database. *JAMA Intern Med*. 2016;176(1):138.

Cheol Seong S, Kim YY, Khang YH, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. *Int J Epidemiol*. 2017;46(3):799–800.

Bae WJ, Choi JB, Moon HW, et al. Influence of diabetes on the risk of urothelial cancer according to body mass index: a 10-year nationwide population-based observational study. *J Cancer*. 2018;9(3):488–493.

Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112(17):2735–2752.

Lee SY, Park HS, Kim DJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. *Diabetes Res Clin Pract*. 2007;75(1):72–80.

Seo JA, Song SW, Han K, et al. The associations between serum zinc levels and metabolic syndrome in the Korean population: findings from the 2010 Korean National Health and Nutrition Examination Survey. *PLoS One*. 2014;9(8):e105990.

Kim J, Lim DH, Han K, et al. Retinal vein occlusion is associated with low blood high-density lipoprotein cholesterol: a nationwide cohort study. *Am J Ophthalmol*. 2019;205:35–42.

Han G, Han J, Han K, et al. Visual acuity and development of Parkinson’s disease: a nationwide cohort study. *Mov Disord*. 2020 Jul 25 [Epub ahead of print].

Stem MS, Talwar N, Comer GM, Stein JD. A longitudinal analysis of risk factors associated with central retinal vein occlusion. *Ophthalmology*. 2013;120(2):362–370.

Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA*. 2001;285(19):2486–2497.

Irving RJ, Walker BR, Noon JP, et al. Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. *Cardiovasc Res*. 2002;53(1):271–276.

Serne EH, Ijzerman RG, de Jongh RT, Stehouwer CD. Blood pressure and insulin resistance: role for microvascular function? *Cardiovasc Res*. 2002;53:271–276. *Cardiovasc Res*. 2002;55(2):418–419; discussion 420-421.

Serne EH, Stehouwer CD, ter Maaten JC, et al. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. *Circulation*. 1999;99(7):896–902.

Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel
mechanism for insulin resistance. *J Clin Invest.* 1990;85(6):1844–1852.
35. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM. *Diabetes.* 1992;41(9):1076–1083.
36. Festa A, D’Agostino R, Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). *Circulation.* 2000;102(1):42–47.
37. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. *Diabetes.* 1999;48(9):1856–1862.
38. Dzau VJ. Atherosclerosis and hypertension: mechanisms and interrelationships. *J Cardiovasc Pharmacol.* 1990;15(Suppl 5):S59–S64.
39. Aronson D, Rayfield EJ. How hyperglycemia promotes atherosclerosis: molecular mechanisms. *Cardiovasc Diabetol.* 2002;1:1.
40. Williams IL, Wheatcroft SB, Shah AM, Kearney MT. Obesity, atherosclerosis and the vascular endothelium: mechanisms of reduced nitric oxide bioavailability in obese humans. *Int J Obes Relat Metab Disord.* 2002;26(6):754–764.
41. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS. Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study. *Arch Intern Med.* 2008;168(9):969–978.
42. Devers MC, Campbell S, Simmons D. Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease. *BMJ Open Diabetes Res Care.* 2016;4(1):e000195.
43. Thomas F, Pannier B, Benetos A, Vischer UM. The impact of the metabolic syndrome–but not hypertension–on all-cause mortality disappears in the elderly. *J Hypertens.* 2011;29(4):663–668.
44. Jamal O, Aneni EC, Shaharyar S, et al. Cigarette smoking worsening systemic inflammation in persons with metabolic syndrome. *Diabetol Metab Syndr.* 2014;6:79.